Lost Women of Science

Lost Women of Science
  • ٤٫٨ (٢١٣)
  • العلوم
Lost Women of Science

For every Marie Curie or Rosalind Franklin whose story has been told, hundreds of female scientists remain unknown to the public at large. In this series, we illuminate the lives and work of a diverse array of groundbreaking scientists who, because of time, place and gender, have gone largely unrecognized. Each season we focus on a different scientist, putting her narrative into context, explaining not just the science but also the social and historical conditions in which she lived and worked. We also bring these stories to the present, painting a full picture of how her work endures.

  1. Lost Women of Science Conversations: Attention is Discovery

    قبل ٣ أيام

    Lost Women of Science Conversations: Attention is Discovery

    Anna Von Mertens' thoughtful new exploration of Henrietta Swan Leavitt's life describes and illuminates Leavitt's decades-long study of stars, including the groundbreaking system she developed for measuring vast distances within our universe simply by looking at photographic plates. Leavitt studied hundreds of thousands of stars captured on the glass plates at the Harvard College Observatory, where she worked as a human computer from the turn of the 20th century until her death in 1921. Von Mertens explores her life, the women she worked alongside, and her discoveries, weaving biography, science, and visual imagery into a rich tapestry that deepens our understanding of the universe and the power of focused, methodical attention.

    ٢٨ من الدقائق
  2. Finding Dora Richardson: The Forgotten Developer of Tamoxifen, a Lifesaving Breast Cancer Therapy - Episode Two

    ٢٨ ربيع الآخر

    Finding Dora Richardson: The Forgotten Developer of Tamoxifen, a Lifesaving Breast Cancer Therapy - Episode Two

    Although initial clinical trials of tamoxifen as a treatment of breast cancer were positive, Imperial Chemical Industries (ICI) did not believe this market would be commercially viable. The company had hoped for a contraceptive pill – tamoxifen didn’t work for that – not a cancer treatment. In 1972 the higher-ups at ICI decided to cancel the research. But Dora Richardson, the chemist who had originally synthesized the compound, and her boss, Arthur Walpole, were convinced they were on to something important, something that could save lives. They continued the research in secret. Tamoxifen was eventually launched in the U.K. in 1973 and went on to become a global success, saving hundreds of thousands of lives. Dora Richardson’s role in its development, however, was overshadowed by her a male colleague and all but forgotten.

    ٣٦ من الدقائق
  3. Finding Dora Richardson - The Forgotten Developer of Tamoxifen

    ٢١ ربيع الآخر

    Finding Dora Richardson - The Forgotten Developer of Tamoxifen

    In the early 1960s, chemist Dr. Dora Richardson synthesized a chemical compound that became one of the most important drugs to treat breast cancer: tamoxifen. Although her name is on the original patent, her contributions have been lost to history.  In the first episode of this two-part podcast, Katie Couric introduces us to Dora’s story. Lost Women of Science producer Marcy Thompson tracked down Dora’s firsthand account of the history of the drug’s development. This document, lost for decades, tells the story of how the compound was made and how Imperial Chemical Industries, where Richardson worked, almost terminated the project because the company was hoping to produce a contraceptive, not a cancer therapy.

    ٤٢ من الدقائق
  4. Lost Women of Science Conversations: Wonder Drug

    ١٤ ربيع الآخر · إضافة

    Lost Women of Science Conversations: Wonder Drug

    While researching her book about thalidomide in America, Jennifer Vanderbes discovered that there were far more survivors in the U.S. than originally thought – at least ten times more. These survivors were born with shortened limbs and other serious medical conditions after their mothers unwittingly took thalidomide in the early 1960s in so-called clinical trials. Wonder Drug tells the story of Vanderbes’ trek across the U.S. in search of these thalidomide survivors. It also revisits the role of the U.S. Food and Drug Administration medical reviewer Dr. Frances Oldham Kelsey – the subject of our recent five-part season – who refused to approve thalidomide for sale in the U.S. In the process of writing her book, Vanderbes became an advocate for the survivors, now in their sixties, and their search for justice and support.

    ٣٧ من الدقائق
  5. The Devil in the Details - Chapter Five

    ٧ ربيع الآخر

    The Devil in the Details - Chapter Five

    It’s September 2024 and a group of American thalidomide survivors arrive in Washington D.C. to lobby the government for support. More than 60 years have gone by since Frances Kelsey first stalled the New Drug Approval application from pharma company Merrell for thalidomide. Although she stopped the drug from going on the market in the U.S., hundreds of pregnant women still took thalidomide in Merrell’s so-called clinical trials, and many had babies with shortened limbs and serious medical conditions. Others had miscarriages or stillborn babies. Here we look at the legacy of thalidomide, the changes in drug regulations in the wake of the scandal, and what happened to our hero, Frances Kelsey.

    ٣٦ من الدقائق
  6. The Devil in the Details - Chapter Four

    ٣٠ ربيع الأول

    The Devil in the Details - Chapter Four

    It’s the summer of 1962 and thalidomide has been off the market in Europe for months. But in the U.S., people are only just beginning to find out about the scandal. The Washington Post breaks the story and puts a picture of Frances Kelsey on the front page. She’s the hero who saved American lives. President John F. Kennedy gives her a medal and her image is splashed across newspapers around the country. At the end of the previous year, Merrell, the company that wanted to sell thalidomide in the U.S., had made a half-hearted attempt to contact some of the doctors who had been given millions of thalidomide samples for so-called clinical trials. Just how many pregnant women might have thalidomide in their medicine cabinets?

    ٣٣ من الدقائق
  7. The Devil in the Details - Chapter Three

    ٢٣ ربيع الأول

    The Devil in the Details - Chapter Three

    It’s 1961 and Widukind Lenz, a German pediatrician, is going door to door in his efforts to find out what is causing the epidemic of babies born with shortened limbs and other serious medical conditions. In the U.S., drug company Merrell is battling with Dr. Frances Kelsey at the Food and Drug Administration about the approval for thalidomide. She’s asking for data that shows it’s safe in pregnancy (spoiler alert: it’s not). Meanwhile, Merrell continues to send hundreds of thousands of thalidomide pills to doctors in so-called clinical trials. In November 1961, Dr. Lenz goes public with the results of his medical sleuthing and, as host Katie Hafner puts it, “the proverbial shit hits the proverbial fan.”

    ٢٩ من الدقائق
  8. The Devil in the Details - Chapter Two

    ١٦ ربيع الأول

    The Devil in the Details - Chapter Two

    It’s the early 1960s and the German pharmaceutical market is booming. A sedative called Contergan is one of the bestselling drugs. Contergan’s active ingredient is thalidomide and it is touted as a wonder drug, a non-addictive sedative safer than barbiturates. In the U.S., the drug is called Kevadon, and its distributor is impatient to get the drug on the market. But Dr. Frances Kelsey, a medical examiner at the U.S. Food and Drug Administration, is stalling the approval of Kevadon. She wants more information from the manufacturer to prove it is safe. Meanwhile, doctors in Scotland and Australia are beginning to suspect thalidomide might, in fact, be very toxic. And in Germany, reports are beginning to emerge of a mysterious epidemic of babies born with missing limbs and other serious medical conditions, but doctors have no idea what's causing it.

    ٣١ من الدقائق
مشاهدة الكل (٩٤)

مقاطع ترويجية

المضيفون والضيوف

٤٫٨
من ٥
‫٢١٣ من التقييمات‬

حول

For every Marie Curie or Rosalind Franklin whose story has been told, hundreds of female scientists remain unknown to the public at large. In this series, we illuminate the lives and work of a diverse array of groundbreaking scientists who, because of time, place and gender, have gone largely unrecognized. Each season we focus on a different scientist, putting her narrative into context, explaining not just the science but also the social and historical conditions in which she lived and worked. We also bring these stories to the present, painting a full picture of how her work endures.

المعلومات

  • صناع العمل
    Lost Women of Science
  • سنوات النشاط
    ١٤٤٣ هـ - ١٤٤٦ هـ
  • الحلقات
    ٩٤
  • التقييم
    ملائم
  • حقوق النشر
    © Copyright 2021 Lost Women of Science
  • موقع البرنامج على الويب
    Lost Women of Science

قد يعجبك أيضًا

للاستماع إلى حلقات ذات محتوى فاضح، قم بتسجيل الدخول.

اطلع على آخر مستجدات هذا البرنامج

قم بتسجيل الدخول أو التسجيل لمتابعة البرامج وحفظ الحلقات والحصول على آخر التحديثات.
تحديد بلد أو منطقة

أفريقيا والشرق الأوسط، والهند

آسيا والمحيط الهادئ

أوروبا

أمريكا اللاتينية والكاريبي

الولايات المتحدة وكندا